The State of Depression in the U.S.

The State of Depression in the U.S

The mental health crisis is a public health emergency that cannot be ignored. After COVID-19, Major Depressive Disorder (MDD) – a mood disorder where depressive symptoms can last consistently for at least a two-week period and affect all aspects of someone’s life – may be one of the most pressing public health crises in the world today.1 However, the standard of care for MDD treatment has been largely unchanged for decades, leaving an urgent need for treatment innovation.

Recent Data Suggests an Ongoing MDD Crisis

  • Approximately 1 in 5 adults in the U.S. (~21 million) experience MDD in their lifetime.2
  • 54% of people with MDD also experience elevated anxiety symptoms.3
  • 3x increase in depressive symptoms in the U.S. during the COVID-19 pandemic.4
  • 34% of adults with depression receive no treatment at all.5

Depression’s Staggering Economic and Societal Costs

  • $326 billion: The most recent estimate (2018) of the economic burden of MDD.6
  • $9,450 per employee: Estimated untreated depression costs in absenteeism and lost productivity in the workforce every year.7

Intergenerational Risk of Depression

  • Data suggests that young people with a depressed parent have a 3x increased risk of MDD.8

Unmet Patient Need Currently Exists

Data from a survey of patients with MDD conducted by Sage Therapeutics

  • 41% have stopped taking antidepressants within 90 days.9
  • 68% expressed dissatisfaction with the amount of time on medication.10
  • 75% expressed frustration because they need to try multiple treatments to find one that works.11

3Gaspersz R, Lamers F, Kent JM, et al. Longitudinal predictive validity of the DSM-5 anxious distress specifier for clinical outcomes in a large cohort of patients with major depressive disorder. J Clin Psychiatry. 2017;78(2):207-213.
5 Updated January 2022. Accessed April 20, 2022.
6Greenberg PE, et al. PharmacoEconomics. 2021. doi: 10.1007/s40273-021-01019-4
7American Heart Association, 2018, CEO Roundtable Report: Mental Health, A Workforce Crisis:
9Arnaud A, et al. J Manag Care Spec Pharm. 2019;S25(10-a):S49-S50. Meeting Abstracts supplement.
10JPM 2022 presentation; Sage Therapeutics, Inc. Data on file; survey of MDD patients conducted by Sage
11JPM 2022 presentation; Sage Therapeutics, Inc. Data on file; survey of MDD patients conducted by Sage

Related Thoughts